Shares of Telomir Pharmaceuticals, Inc. (NASDAQ:TELO - Get Free Report) shot up 3.8% on Monday . The stock traded as high as $4.42 and last traded at $4.38. 41,805 shares traded hands during mid-day trading, a decline of 47% from the average session volume of 78,525 shares. The stock had previously closed at $4.22.
Telomir Pharmaceuticals Stock Down 4.3 %
The stock has a 50 day simple moving average of $5.29 and a 200-day simple moving average of $5.16.
Telomir Pharmaceuticals (NASDAQ:TELO - Get Free Report) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.05) earnings per share for the quarter.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently modified their holdings of TELO. Beaird Harris Wealth Management LLC increased its stake in Telomir Pharmaceuticals by 212.9% in the 2nd quarter. Beaird Harris Wealth Management LLC now owns 14,623 shares of the company's stock valued at $70,000 after purchasing an additional 9,950 shares in the last quarter. Suncoast Equity Management boosted its stake in shares of Telomir Pharmaceuticals by 109.9% during the 3rd quarter. Suncoast Equity Management now owns 51,194 shares of the company's stock valued at $329,000 after buying an additional 26,803 shares during the last quarter. Finally, Bank of New York Mellon Corp acquired a new position in shares of Telomir Pharmaceuticals in the 2nd quarter worth approximately $241,000.
Telomir Pharmaceuticals Company Profile
(
Get Free Report)
Telomir Pharmaceuticals, Inc, a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems.
Recommended Stories
Before you consider Telomir Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Telomir Pharmaceuticals wasn't on the list.
While Telomir Pharmaceuticals currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
